Reports on long-term (≥10 years) effects of cancer vaccines are missing. Therefore， in 2002， we initiated a phase I/II trial in cutaneous melanoma patients to further explore the immunogenicity of our DC vaccine and to establish its long-term toxicity and clinical benefit after a planned 10-year followup.
Reports on long-term (≥10 years) effects of cancer vaccines are missing. Therefore， in 2002， we initiated a phase I/II trial in cutaneous melanoma patients to further explore the immunogenicity of our DC vaccine and to establish its long-term toxicity and clinical benefit after a planned 10-year followup.
